Myomo (NYSEAMERICAN:MYO – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02), FiscalAI reports. Myomo had a negative net margin of 33.53% and a negative return on equity of 138.85%. The company had revenue of $12.33 million for the quarter, compared to analyst estimates of $11.51 million.
Myomo Trading Up 15.7%
Shares of MYO traded up $0.19 during mid-day trading on Monday, hitting $1.40. The company had a trading volume of 341,790 shares, compared to its average volume of 536,082. Myomo has a 1-year low of $0.60 and a 1-year high of $1.89. The company has a quick ratio of 2.01, a current ratio of 2.31 and a debt-to-equity ratio of 1.98. The business’s 50-day simple moving average is $1.38 and its 200-day simple moving average is $1.09. The stock has a market cap of $55.45 million, a PE ratio of -4.12 and a beta of 1.74.
Insider Buying and Selling at Myomo
In related news, insider Harry Kovelman sold 17,250 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $1.73, for a total value of $29,842.50. Following the transaction, the insider directly owned 105,983 shares of the company’s stock, valued at approximately $183,350.59. This trade represents a 14.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 47,738 shares of company stock valued at $70,662. Company insiders own 12.14% of the company’s stock.
Myomo Company Profile
Myomo, Inc is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user’s residual muscle signals and assists movement of the arm and hand.
The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.
Featured Stories
- Five stocks we like better than Myomo
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.
